Objective: To explore the advantages of Shensong Yangxin capsule in elderly patients with acute myocardial infarction. Methods: From February 2018 to January 2019, 108 elderly patients with acute myocardial infarction were divided into observation group and control group, according to the method of random number table. The control group was treated by routine method, and the observation group used Shensong Yangxin capsule on the basis of routine treatment. The clinical efficacy, adverse reactions, levels of inflammatory factors before and after treatment and cardiac function were compared between the two groups. Results: The total effective rate of treatment in the observation group was 96.30%, and that in control group was 83.33%; the difference between the two groups was statistically significant (χ²=4.96, P<0.05). There was no statistical difference in CRP, IL-6, TNF-α before the treatment between the two groups (P>0.05); and after the treatment there were significant differences in the above indexes between the two groups (all P<0.05). There was no significant difference in left ventricular end diastolic diameter (LVEDD), left ventricular end-systolic dimension (LVESD), left ventricular ejection fraction (LVEF) before the treatment between the two groups (P>0.05); there were significant differences in the above indexes between the two groups after the treatment (all P<0.05). The incidence of adverse reactions in the observation group was 7.14%, and the incidence of adverse reactions in the control group was 5.56%; there was no significant difference between the two groups (χ²=0.15, P>0.05). Conclusion: Shensong Yangxin capsule can effectively improve the clinical efficacy of elderly patients with acute myocardial infarction, improve the level in inflammatory factors and cardiac function indicators, without obvious adverse reactions. It is an effective and safe method for treatment.